National Cancer Institute (NCI): all 3,554 studies

Page 21 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasActive, not recruitingNCT02407405Phase 2
• FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine TherapyActive, not recruitingNCT02398773Phase 2
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid CancerWithdrawnNCT02390739Phase 1/2
• Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation TherapyActive, not recruitingNCT02381561Phase 1
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedNCT02381548Phase 1
• Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and CisplatinCompletedNCT02381535Phase 1
• Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsCompletedNCT02379416Phase 1
• Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaActive, not recruitingNCT02359565Phase 1
• A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaActive, not recruitingNCT02339571Phase 2/3
• DoD-NCI TRICARE Feasibility StudyCompletedNCT02339025
• Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care TreatmentCompletedNCT02326857
• Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal TumorsCompletedNCT02319018Phase 1
• Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced CancerCompletedNCT02317874Phase 1
• Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close OtherCompletedNCT02317380
• Self-Affirmation: Construct ValidityCompletedNCT02317367
• Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell MalignanciesCompletedNCT02315612Phase 1
• Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT02311920Phase 1
• Self-Affirmation, Emotion, and Alcohol ConsumptionCompletedNCT02311400
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
• Improving Cervical Cancer Screening Among HIV-Infected Women in IndiaCompletedNCT02247999
• Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to TreatmentActive, not recruitingNCT02243592
• Iloprost in Preventing Lung Cancer in Former SmokersCompletedNCT02237183Phase 1
• Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated LymphomasWithdrawnNCT02228512Phase 1/2
• Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02227901Phase 1
• Comparison of Two Dose Assessment Methods for Exposures to Nuclear Detonation RadiationCompletedNCT02226874
• Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02219737Phase 1
• Study of Diets and Way of Life of Native Americans and Hispanics in New Mexico During the Time of the Trinity Nuclear TestCompletedNCT02211781
• Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1CompletedNCT02211768Phase 1
• Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid TumorsCompletedNCT02211755Phase 1
• Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
• Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS LymphomaActive, not recruitingNCT02203526Phase 1
• Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingNCT02196181Phase 2
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02193282Phase 3
• Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal CancerCompletedNCT02188264Phase 1
• Feasibility of Identifying a Chinese Study Population and Eligible Pediatric Cancer Cases, and Linking the Two Groups to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer.WithdrawnNCT02160795
• Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02160015Phase 1
• Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell LymphomaActive, not recruitingNCT02159755Phase 1
• EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung CancerCompletedNCT02154399Phase 2
• Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain TumorsCompletedNCT02153957Phase 2
• Internet Support Group for Parents of a Child With Neurofibromatosis Type 1CompletedNCT02153931
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
• Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionTerminatedNCT02134886Phase 1
• Sapanisertib Before and After Surgery in Treating Patients With Recurrent GlioblastomaTerminatedNCT02133183Phase 1
• Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
• Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With CancerCompletedNCT02108028
• A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid TumorsCompletedNCT02107963Phase 1
• Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02101944Phase 1
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade GliomaCompletedNCT02101905Phase 1
• Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy VolunteersCompletedNCT02099136Phase 2
• Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy VolunteersCompletedNCT02090933Phase 2
• Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic DysfunctionCompletedNCT02070549Phase 1
• Blood Collection From People With Ovarian CancerCompletedNCT02063464
• Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch SyndromeCompletedNCT02052908Phase 1
• Study of Variation Over Time in the Oral MicrobiomeCompletedNCT02049398
• Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02042430Early Phase 1
• Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02029950Phase 1
• Study to Evaluate the Natural History of Head and Neck Cancer Precursors in TaiwanCompletedNCT02017288
• Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain MetastasesActive, not recruitingNCT02015117Phase 1
• Natural History and Tissue Acquisition Study of Adrenocortical CarcinomaCompletedNCT02015026
• Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaActive, not recruitingNCT01989585Phase 1/2
• Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By SurgeryCompletedNCT01989559Phase 1
• A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni SyndromeCompletedNCT01981525Phase 1
• Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT01955499Phase 1
• Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryActive, not recruitingNCT01947023Phase 1
• Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01940809Phase 1
• Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01935973Phase 1
• Retinoid 9cUAB30 in Preventing Cancer in Healthy VolunteersCompletedNCT01935960Phase 1
• Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck CancerCompletedNCT01935921Phase 1
• Study of the Drug Ipilimumab for Metastatic Merkel Cell CarcinomaWithdrawnNCT01913691Phase 2
• Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryTerminatedNCT01912625Phase 1
• Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver DysfunctionTerminatedNCT01907802Phase 1
• Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01902160Phase 1
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
• Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT01896999Phase 1/2
• Antibody Treatment for Advanced Celiac DiseaseCompletedNCT01893775Phase 1
• Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01886859Phase 1
• Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing SurgeryTerminatedNCT01886573Phase 1
• Evaluation of National Cancer Institute Young Adult Stop-Smoking ProgramCompletedNCT01885052Phase 2
• Breast Tissue Study of Breast Diseases Among Women in Hong KongCompletedNCT01885039
• NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid TumorsCompletedNCT01875601Phase 1
• Study of Lung Health Among Workers Exposed to Diesel ExhaustCompletedNCT01867450
• Cigarette Smoking and Oral MicrobiotaCompletedNCT01862809
• Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01861314Phase 1
• Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By SurgeryWithdrawnNCT01859182Phase 2
• Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaWithdrawnNCT01851408Phase 2
• Rapid Autopsy and Procurement of Cancer TissueTerminatedNCT01851395
• Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for ResearchCompletedNCT01851382
• Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent GlioblastomaCompletedNCT01849146Phase 1
• Ibrutinib in Treating Patients With Relapsed Hairy Cell LeukemiaActive, not recruitingNCT01841723Phase 2
• Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By SurgeryTerminatedNCT01835184Phase 1
• Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular LymphomaActive, not recruitingNCT01829568Phase 1
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
• Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck CancerSuspendedNCT01810913Phase 2/3
• Indenoisoquinoline LMP400 for Advanced Solid Tumors and LymphomasCompletedNCT01794104Phase 1
• Endometrial Cancer Testing With Vaginal and Endometrial Cell SamplesCompletedNCT01793545
• Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT01783171Phase 1
• Colon Cancer Study of Fecal Samples in Shanghai, ChinaCompletedNCT01778595
• Perspective-taking, and Examining the Clinical Trial Informed Consent ProcessCompletedNCT01778582
• Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01757639Phase 1

← National Cancer Institute (NCI) overview and focus areas